Engelstein D, Kahan E, Servadio C
Department of Urology, Beilinson Medical Center, Petah Tiqva, Israel.
J Urol (Paris). 1992;98(2):98-100.
A prospective, randomized, double-blind study was performed on 87 patients with ureterolithiasis, assessing the effect of the essential oil preparation Rowatinex (Rowa Pharmaceuticals, Ireland) for the treatment of ureterolithiasis. Forty-three patients were treated with Rowatinex and 44 patients with placebo. Despite the larger average diameter of calculi in the group of patients treated with Rowatinex, the overall stone expulsion rate was significantly higher in the Rowatinex group as compared to placebo: 81% and 59%, respectively (0.025 > p > 0.01). This higher rate of stone expulsion is observed in patients with disappearance of pretreatment ureteral dilatation (when patients with expelled stones are excluded) (0.05 > p > 0.001). Seven patients in the Rowatinex group had mild to moderate gastrointestinal disturbances; no other significant side effects were noted during the treatment in either group. We conclude that early treatment with Rowatinex for patients with ureteral stones is indicated before other more aggressive measures are considered.
对87例输尿管结石患者进行了一项前瞻性、随机、双盲研究，评估精油制剂Rowatinex（爱尔兰罗瓦制药公司）治疗输尿管结石的效果。43例患者接受Rowatinex治疗，44例患者接受安慰剂治疗。尽管接受Rowatinex治疗的患者组结石平均直径较大，但Rowatinex组的总体结石排出率显著高于安慰剂组：分别为81%和59%（0.025＞p＞0.01）。在治疗前输尿管扩张消失的患者中观察到更高的结石排出率（排除结石已排出的患者）（0.05＞p＞0.001）。Rowatinex组有7例患者出现轻度至中度胃肠道不适；两组治疗期间均未发现其他明显副作用。我们得出结论，对于输尿管结石患者，在考虑采取其他更积极的措施之前，建议尽早使用Rowatinex进行治疗。
